Edition:
United States

Hologic Inc (HOLX.OQ)

HOLX.OQ on NASDAQ Stock Exchange Global Select Market

44.00USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$44.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
903,106
52-wk High
$46.80
52-wk Low
$35.78

Chart for

About

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays,... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $12,130.08
Shares Outstanding(Mil.): 275.68
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.57 18.09
EPS (TTM): -- -- --
ROI: -- 9.94 33.19
ROE: -- 15.12 17.57

BRIEF-Third Respiratory Assay now FDA cleared on Hologic's new Panther Fusion system

* THIRD RESPIRATORY ASSAY NOW FDA CLEARED ON HOLOGIC'S NEW PANTHER FUSION® SYSTEM

Dec 06 2017

BRIEF-HOLOGIC RECEIVES FDA 510(K) CLEARANCE OF QUANTRA 2.2 BREAST DENSITY ASSESSMENT SOFTWARE

* HOLOGIC RECEIVES FDA 510(K) CLEARANCE OF QUANTRA 2.2 BREAST DENSITY ASSESSMENT SOFTWARE

Nov 24 2017

BRIEF-Hologic announces upcoming put option

* Hologic announces upcoming put option and notice of redemption of 2.00% convertible senior notes due 2043 Source text for Eikon: Further company coverage:

Nov 14 2017

BRIEF-Hologic announces Q4 GAAP earnings per share $0.29

* Hologic announces financial results for fourth quarter of fiscal 2017

Nov 08 2017

BRIEF-Hologic - ‍received 510(k) clearance from FDA for Panther Fusion Paraflu assay​

* Hologic Inc - ‍received 510(k) clearance from FDA for Panther Fusion Paraflu assay​ Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-Hologic prices offering of $350 mln 4.375 pct senior notes due 2025

* Hologic announces pricing of offering of $350 million aggregate principal amount of 4.375% senior notes due 2025

Oct 04 2017

BRIEF-Hologic announces offering of $350 mln of senior notes due 2025

* Hologic announces offering of $350 million of senior notes due 2025

Oct 04 2017

BRIEF-Hologic enters into amended and restated five-year secured credit agreement

* Hologic enters into amended and restated five-year secured credit agreement

Oct 04 2017

BRIEF-Hologic receives FDA 510(k) clearance to market SculpSure

* Hologic receives FDA 510(k) clearance to market SculpSure for non-invasive body contouring (lipolysis) of the submental area (under the chin)

Sep 27 2017

BRIEF-Hologic updates on commercial availability of Brevera Breast Biopsy System

* Hologic inc - ‍U.S. commercial availability of Brevera Breast Biopsy System with Corlumina imaging technology​ Source text for Eikon: Further company coverage:

Aug 31 2017

Earnings vs. Estimates